Covid-19: Recovery fee touches 90%; solely eight.5% of whole caseload energetic in India – Home Health Choices
NEW DELHI: With a complete of 70,78,123 individuals having recuperated…Latest Updates
AuraVax, nevertheless, has the choice to completely license a brand new intranasal vaccine know-how developed by its Indian-American co-founder, Navin Varadarajan, M.D. Anderson Professor of Chemical and Biomolecular Engineering on the University of Houston.
“A safe and durable vaccine is urgently needed to tackle the Covid-19 pandemic that has infected millions of people and caused over 620,000 deaths globally,” Vardarajan informed .
“We plan to stop Covid-19, a respiratory virus, at its point of entry – the nasal cavity – and we believe our intranasal platform is a differentiated approach that will lead to a vaccine with increased efficacy to create sustained immunity to Covid-19,” he stated.
Based on pre-clinical experiments, Varadarajan stories his know-how not solely elicits a mucosal immune response, but additionally systemic immunity, based on the UoH.
Varadarajan is concentrating on the spike proteins, which permit infections to penetrate host cells, in his research. The professor additionally prefers proteins due to their means to induce sturdy immune responses, flexibility and scalability, and the absence of infectious particles, as per an UoH assertion.
AuraVax describes its vaccine administration platform as ‘next-generation’, one which may very well be administered at dwelling.
“We are excited to be collaborating with the University of Houston and look forward to future success by advancing the development of this novel intranasal vaccine platform to address a multitude of respiratory viruses, starting with Covid-19. We plan to stop Covid-19, a respiratory virus, at its point of entry — the nasal cavity — and we believe our intranasal platform is a differentiated approach that will lead to a vaccine with increased efficacy to create sustained immunity to Covid-19,” stated Varadarajan.
“AuraVax, being created by an UoH professor, is the ideal partner for us, and what better cause than to advance the creation of a vaccine to Covid-19, arguably the primary challenge facing our generation. The partnership has my wholehearted support,” stated Amr Elnashai, University of Houston vice chairman for analysis and know-how switch.
“The race for more effective ways of vaccinating against Covid-19 and other respiratory diseases has led to a broad and extensive focus on various protective mechanisms of action. Based on pre-clinical work, our technology not only elicits a mucosal immune response, but also systemic immunity. We believe AuraVax has a competitive advantage given the immune responses and a supply chain that is well-suited for widespread distribution and self-administration distribution,” stated Dr Varadarajan.